These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 22102173

  • 1. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
    Cheng J, Ha M, Wang Y, Sun J, Chen J, Wang Y, Tong C.
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
    [Abstract] [Full Text] [Related]

  • 2. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
    Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, Sun J.
    Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
    [Abstract] [Full Text] [Related]

  • 3. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP, Shen H, Liu LX, Shu YQ.
    Gene; 2013 Sep 10; 526(2):265-74. PubMed ID: 23727606
    [Abstract] [Full Text] [Related]

  • 4. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
    Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A, Bio-FAST trial group.
    Br J Cancer; 2013 Apr 30; 108(8):1695-703. PubMed ID: 23549037
    [Abstract] [Full Text] [Related]

  • 5. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.
    Cancer Invest; 2010 Dec 30; 28(10):1078-83. PubMed ID: 20504223
    [Abstract] [Full Text] [Related]

  • 6. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P.
    Ann Oncol; 2004 Aug 30; 15(8):1194-203. PubMed ID: 15277258
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Lung Cancer; 2013 Nov 30; 82(2):288-93. PubMed ID: 24045016
    [Abstract] [Full Text] [Related]

  • 8. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 30; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.
    Cancer Chemother Pharmacol; 2014 Oct 30; 74(4):777-86. PubMed ID: 25107571
    [Abstract] [Full Text] [Related]

  • 10. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
    Li P, Wang YD, Cheng J, Chen JC, Ha MW.
    Tumour Biol; 2015 Dec 30; 36(12):9465-73. PubMed ID: 26124006
    [Abstract] [Full Text] [Related]

  • 11. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY, Ho CC, Tsai TH, Chen KY, Shih JY, Yu CJ.
    Lung Cancer; 2018 Apr 30; 118():90-96. PubMed ID: 29572009
    [Abstract] [Full Text] [Related]

  • 12. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
    Han JY, Lee GK, Lim KY, Lee YJ, Nam BH, Lee JS.
    Cancer Res Treat; 2017 Jul 30; 49(3):678-687. PubMed ID: 27737534
    [Abstract] [Full Text] [Related]

  • 13. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 30; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 14. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 30; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 15. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
    Grenda A, Błach J, Szczyrek M, Krawczyk P, Nicoś M, Kuźnar Kamińska B, Jakimiec M, Balicka G, Chmielewska I, Batura-Gabryel H, Sawicki M, Milanowski J.
    Cancer Med; 2020 Jan 30; 9(2):605-614. PubMed ID: 31797573
    [Abstract] [Full Text] [Related]

  • 16. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
    Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J.
    J Thorac Oncol; 2012 Apr 30; 7(4):663-71. PubMed ID: 22425915
    [Abstract] [Full Text] [Related]

  • 17. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer.
    Li C, Liu M, Yan A, Liu W, Hou J, Cai L, Dong X.
    Tumour Biol; 2014 Dec 30; 35(12):12707-12. PubMed ID: 25217323
    [Abstract] [Full Text] [Related]

  • 18. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
    Li J, Li ZN, Du YJ, Li XQ, Bao QL, Chen P.
    Clin Lung Cancer; 2009 Nov 30; 10(6):414-21. PubMed ID: 19900859
    [Abstract] [Full Text] [Related]

  • 19. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
    Zhang L, Liu T, Zhang JQ.
    Zhonghua Zhong Liu Za Zhi; 2011 Mar 30; 33(3):212-6. PubMed ID: 21575522
    [Abstract] [Full Text] [Related]

  • 20. ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.
    Xu ZC, Cai HZ, Li X, Xu WZ, Xu T, Yu B, Zou Q, Xu L.
    Genet Mol Res; 2016 May 23; 15(2):. PubMed ID: 27323074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.